Therefore, we have proposed that the critical mechanism through which emodin sensitizes HCC cells to the anti-cancer effects of sorafenib is the suppression of AKT and STAT3 oncogenic growth signaling caused by decreases in intracellular cholesterol. Here, STAT3 is linked to cancer.